Astellas Pharma Inc. (ALPMF)
OTC PINK OTC PINK Primary 
Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2024 Earnings Conference Call April 25, 2025 4:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IR Officer Naoki Okamura - Representative Director, President & Chief Executive Officer Claus Zieler - Chief Commercial Officer & Medical Affairs Officer Tadaaki Taniguchi - Chief Medical Officer Atsushi Kitamura - Chief Financial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Seiji Wakao - JPMorgan Securities Akinori Ueda - Goldman Sachs Securities Shinichiro Muraoka - Morgan Stanley MUFG Securities Hiroyuki Matsubara - Nomura Securities Miki Sogi - Sanford C. Bernstein Kazuaki Hashiguchi - Daiwa Securities Fumiyoshi Sakai - UBS Securities Hiromitsu Ikeda Thank you very much for joining our FY 2024 Financial Results Announcement Meeting by Astellas Pharma Inc. out of your very busy schedule today.
Astellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline Forward
Astellas Pharma Inc. has a diverse pipeline with significant growth in oncology, driven by new approvals for drugs like zolbetuximab. Despite recent stock declines, ALPMF's revenue and core profits have grown, supported by strong sales of enzalutamide and faster-than-expected zolbetuximab market penetration. Operational expenses have increased due to amortization and terminated projects, impacting operating profit, but new product launches and approvals indicate potential for future growth.
Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q3 2024 Earnings Conference Call February 4, 2025 2:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IR Officer Atsushi Kitamura - Chief Financial Officer Tadaaki Taniguchi - Chief Medical Officer Claus Zieler - Chief Commercial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Seiji Wakao - JPMorgan Securities Shinichiro Muraoka - Morgan Stanley MUFG Securities Akinori Ueda - Goldman Sachs Securities Hiroyuki Matsubara - Nomura Securities Shinichiro Hyogo - Mitsubishi UFJ Trust Bank Miki Sogi - Sanford C. Berstein Fumiyoshi Sakai - UBS Securities Kazuaki Hashiguchi - Daiwa Securities Hiromitsu Ikeda Thank you very much for your attendance on to this Q3 Y-to-D FY '24 Financial Results Announcement Meeting.
Astellas Pharma Inc. (ALPMF) Q1 2024 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q1 2024 Earnings Conference Call August 1, 2024 3:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IRO Tadaaki Taniguchi - CMO Claus Zieler - CCO Atsushi Kitamura - CFO Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Seiji Wakao - JPMorgan Securities Akinori Ueda - Goldman Sachs Securities Kasumi Haruta - UBS Securities Shinichiro Muraoka - Morgan Stanley MUFG Securities Kazuaki Hashiguchi - Daiwa Securities Shinichiro Hyogo - Mitsubishi UFJ Trust and Banking Corporation Miki Sogi - Sanford C. Bernstein Tony Ren - Macquarie Capital Operator Hiromitsu Ikeda Everyone, thank you so much for your participation in this Financial Results ended June 30th Financial Call.
